Neuren’s DAYBUE Gains Canadian Approval, Expanding Market

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals has announced that DAYBUE™ (trofinetide), the first and only approved treatment for Rett syndrome, has received marketing authorization in Canada, marking a significant milestone for the company. This approval allows Neuren to add potential Canadian sales to their US sales, impacting the calculation of their royalties and sales milestone payments. This development is part of Neuren’s broader strategy to expand DAYBUE’s access beyond the United States.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.